A Phase Ib/II Study of IV Nivolumab and Intrapleural Talimogene Laherparepvec for Patients With Malignant Pleural Effusion
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Nivolumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Cancer metastases; Malignant pleural effusion
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2018 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 21 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Dec 2018.
- 27 Jul 2018 New trial record